Replies to post #4041 on GTC Biotherapeutics (fka GTCB)

[genisi]

Kamada-
I have this question written in my notebook for their next presentation.

[genisi]

Kamada-
What I can think of is the argument that the inhaled form will be
cheaper and easier hence more patients will be able to be treated.

[genisi]

"Why does Kamada have an orphan designation for the inhaled form of AAT but not for the injected form?"

Because there are already 3 approved AAT drugs for IV use in the market but none for use by Inhalation.

(Reply given by their CEO)